A SURGICAL WINDOW-OF-OPPORTUNITY CLINICAL TRIAL EVALUATING THE PCSK9 INHIBITOR EVOLOCUMAB IN PATIENTS WITH GLIOMA

被引：0

作者：

Singh, Kirit ^{[1
]}

Hotchkiss, Kelly ^{[2
]}

Foster, Matthew ^{[3
]}

Railton, Chelsea ^{[4
]}

Blandford, Emily ^{[2
]}

Thomas, Elizabeth ^{[5
]}

Miller, Elizabeth S. ^{[6
]}

Ashley, David ^{[7
]}

Desjardins, Annick

Friedman, Henry ^{[8
]}

Johnson, Margaret O. ^{[6
]}

Friedman, Allan ^{[9
]}

Keir, Steve ^{[10
]}

Herndon, James ^{[11
]}

Sampson, John ^{[2
]}

Li, Chuan-Yuan ^{[12
]}

Fecci, Peter ^{[9
]}

Patel, Anoop ^{[9
]}

Khasraw, Mustafa ^{[4
]}

机构：

[1] Duke Brain Tumor Immunotherapy Program, Durham, NC USA

[2] Duke Univ, Durham, NC USA

[3] Duke Prote & Metabol core, Durham, NC USA

[4] Duke Brain Tumor Immunotherapy Program, Durham, NC USA

[5] Duke Univ Brain Tumor Biorepository, Durham, NC USA

[6] Duke Univ, Sch Med, Preston Robert Tisch Brain Tumor Ctr, Dept Neurosurg, Durham, NC USA

[7] Preston Robert Tisch Brain Tumor Ctr, Durham, NC USA

[8] Preston Robert Tisch Brain Tumor Ctr, Dept Neurosurg, Durham, NC USA

[9] Duke Univ, Dept Neurosurg, Durham, NC USA

[10] Duke Univ, Sch Med, Durham, NC USA

[11] Duke Canc Inst, Dept Biostat, Durham, NC USA

[12] Duke Canc Inst, Durham, NC USA

来源：

NEURO-ONCOLOGY | 2023年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CTIM-10

引用

页数：1

共 50 条

[1] A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma
Singh, Kirit
Foster, Matthew
Miller, Elizabeth S.
Gregory, Simon
Weinhold, Kent J.
Ashley, David M.
Desjardins, Annick
Low, Justin
Peters, Katherine B.
Severance, Erin
Jaggers, Denise
Friedman, Henry S.
Johnson, Margaret O.
Friedman, Allan H.
Keir, Stephen T.
Herndon, James Emmett
Li, Chuan-Yuan
Fecci, Peter E.
Sampson, John H.
Khasraw, Mustafa
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
Kasichayanula, Sreeneeranj
Grover, Anita
Emery, Maurice G.
Gibbs, Megan A.
Somaratne, Ransi
Wasserman, Scott M.
Gibbs, John P.
CLINICAL PHARMACOKINETICS, 2018, 57 (07) : 769 - 779
[3] Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
Sreeneeranj Kasichayanula
Anita Grover
Maurice G. Emery
Megan A. Gibbs
Ransi Somaratne
Scott M. Wasserman
John P. Gibbs
Clinical Pharmacokinetics, 2018, 57 : 769 - 779
[4] Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
Rosenson, Robert S.
Jacobson, Terry A.
Preiss, David
Djedjos, C. Stephen
Dent, Ricardo
Bridges, Ian
Miller, Michael
CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 (03) : 305 - 313
[5] Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
Robert S. Rosenson
Terry A. Jacobson
David Preiss
C. Stephen Djedjos
Ricardo Dent
Ian Bridges
Michael Miller
Cardiovascular Drugs and Therapy, 2016, 30 : 305 - 313
[6] Reduction in Total Cardiovascular Events With the PCSK9 Inhibitor Evolocumab in Patients With Cardiovascular Disease in the FOURIER Trial
Murphy, Sabina A.
Pedersen, Terje R.
Gaciong, Zbigniew A.
Ceska, Richard
Ezhov, Marat V.
Connolly, Derek
Kraydashenko, Oleg
Jukema, J. Wouter
Toth, Kalman
Tikkanen, Matti J.
Im, Kyungah
Wiviott, Stephen D.
Kurtz, Christopher
Honarpour, Narimon
Giugliano, Robert P.
Keech, Anthony C.
Sever, Peter S.
Sabatine, Marc S.
CIRCULATION, 2017, 136
[7] Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
Robert S. Rosenson
Terry A. Jacobson
David Preiss
Stephen C. Djedjos
Ricardo Dent
Ian Bridges
Michael Miller
Cardiovascular Drugs and Therapy, 2016, 30 : 537 - 537
[8] WINDOW-OF-OPPORTUNITY CLINICAL TRIAL OF PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS
de Groot, John
Penas-Prado, Marta
Mandel, Jacob
O'Brien, Barbara
Weathers, Shiao-Pei
Loghin, Monica
Kamiya-Matsuoka, Carlos
Zhou, Shouhao
Colen, Rivka
Hunter, Kathy
Fuller, Gregory
Huse, Jason T.
Rao, Ganesh
Weinberg, Jeffrey
Prabhu, Sujit
Ferguson, Sherise
Yuan, Ying
Vence, Luis
Allison, James
Sharma, Padmanee
Heimberger, Amy
NEURO-ONCOLOGY, 2018, 20 : 2 - 2
[9] Efficacy and Safety of the PCSK9 Inhibitor Evolocumab (AMG 145) in Patients with Type 2 Diabetes
Sattar, Naveed A.
Djedjos, C. Stephen
Robinson, Jennifer G.
Preiss, David
Elliott, Mary
Somaratne, Ransi
Wasserman, Scott M.
Raal, Frederick J.
DIABETES, 2015, 64 : A68 - A68
[10] Regression of Coronary Atherosclerosis With the PCSK9 Inhibitor Evolocumab in Patients With Coronary Artery Disease and Diabetes
King, Peta
Puri, Rishi
Koenig, Wolgang
Brennan, Danielle M.
Somaratne, Ransi
Kassahun, Helina
Wasserman, Scott M.
Nissen, Steven E.
Nicholls, Stephen J.
CIRCULATION, 2017, 136

← 1 2 3 4 5 →